Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of zasocitinib in active psoriatic arthritis
2025-522586-30-00Phase 3Authorised
- Sponsor
- Takeda
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 28
01
Overview
Phase 3, open-label, single-arm trial of zasocitinib in psoriatic arthritis (PsA), sponsored by Takeda. Primary endpoints: Incidence of treatment-emergent adverse events, Incidence of serious adverse events and 2 more. Planned start Jun 2026; status: authorised.
02
Drugs
zasocitinib
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2025-522586-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522586-30-00.